Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz1/2. fázis

Sublingual Dexmedetomidine for Treating Opioid Withdrawal

A legfontosabb adatok

Ki végzi
New York State Psychiatric Institute
Hol
Eatontown, Marlton, New Haven és New York (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Fut, nem toboroz
Fázis
1/2. fázis
Résztvevők
160 fő, tervezett
Kezdés
2023. febr. 28.
Várható befejezés
2027. febr. 28.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • BXCL501 (180 micrograms)
  • BXCL501 (240 micrograms)
  • Placebo
  • Lofexidine (Positive Control)
A regiszteradat frissítve
2026. október 28.

Ki vehet részt

Életkor
18 év – 60 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Capable of understanding and complying with the protocol
  • 18 years of age or older but less than 60 years old
  • Has opioid use disorder moderate-to-severe (304.00) as per DSM-V, and physiological dependence on opioids
  • Females agree to use an acceptable method of contraception for the duration of the study

Ki nem vehet részt

  • Use of oral naltrexone for ≥7 consecutive days within 60 days prior to screening
  • Participation in a clinical trial of a pharmacological agent within 30 days prior to screening
  • Use of any concomitant medication at screening or anticipated/required use during the study period that the investigators feel may impact participant safety or interfere with the aims of the trial (e.g., daily licit or illicit benzodiazepine use)
  • Clinically significant history of cardiac disease, including syncope, bradycardia, conduction abnormalities, orthostatic hypotension or blood pressure disorders. Heart rate and blood pressure at screening and baseline of < 50 beats per minute or systolic blood pressure <105, >150 mmHg or diastolic BP <70, >90 mmHg
  • Any psychiatric disorder that would compromise ability to complete study requirements [e.g. severe acute depression, active mania, or suicidality with specific plan and intent (assessed using the CSSRS)]
  • Positive urine or serum pregnancy test at screening, after admission, planning to become pregnant during the course of the trial, or currently breast feeding
  • Clinically significant medical condition or observed abnormalities (including: physical examination, hypotension, laboratory evaluation, and/or urinalysis findings). Clinically significant abnormal ECG such as second- or third-degree heart block, uncontrolled arrhythmia, or QTc interval > 450 msec for males, and > 470 msec for females
  • Evidence of hepatic abnormalities, including: ascites, bilirubin >10% above upper limit of normal and/or esophageal variceal disease, active hepatitis/aspartate aminotransferase, alanine aminotransferase >3x the upper limit of normal
  • Not being able to provide a negative urine for methadone or buprenorphine at screening
  • Need for alcohol or benzodiazepine detoxification
  • Any finding that, in the view of the principal investigator, would compromise the subject's ability to fulfill the protocol visit schedule or visit requirements
  • Investigator-site personnel or immediate family of investigator-site personnel

Helyszínek itt: Egyesült Államok

  • CLINiLABSEatontown, Egyesült Államok
  • CenExel-HRIMarlton, Egyesült Államok
  • Yale UniversityNew Haven, Egyesült Államok
  • New York State Psychiatric InstituteNew York, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

A major challenge to seeking treatment for opioid use disorder (OUD) is the withdrawal symptoms associated with cessation of opioid use. The signs and symptoms of opioid withdrawal include irritability, anxiety, muscular and abdominal pains, chills, nausea, diarrhea, yawning, runny eyes and nose, sweating, sneezing, weakness, and insomnia. The current gold standard of treatment involves a gradual reduction of the opioid drug dosage (tapering). However, as all opioids have potential for abuse and require careful dosing due to side effects (e.g., respiratory depression), a non-opioid medication to facilitate withdrawal severity would be of great value. Commonly used non-opioid medications like lofexidine have concerning side effects including sedation and low blood pressure. BioXcel Therapeutics has developed BXCL501 (dexmedetomidine: sublingual film) to reduce symptoms associated with opioid withdrawal. Dexmedetomidine is currently used as an intravenous anesthetic for its anxiety-reducing, sedative, and analgesic properties. The current study will seek to compare the safety and efficacy of BXCL501 relative to lofexidine and placebo in subjects with OUD who are physically dependent on opioids. Throughout a 7-day inpatient withdrawal period (using a methadone taper) opioid-dependent participants will receive sublingual BXCL501, placebo, or lofexidine. In comparison to lofexidine, dexmedetomidine is expected to have a superior safety profile with limited adverse effects on blood pressure and heart rhythm. Three sites will participate in this study: NYSPI, Clinilabs, Inc., and Yale University.

A teljes eredeti leírásKevesebb

The NYSPI site is currently paused and has been paused since an institutional pause on human subjects research began in June 2023. The U.S. Department of Health and Human Services (HHS) Office of Human Research Protections (OHRP) issued an FWA restriction on NYSPI research that also included a pause of human subjects research as of June 23, 2023.

A vizsgálat 4 csoportja

  • BXCL501 (180 micrograms)A vizsgált kezelés

    The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.

  • BXCL501 (240 micrograms)A vizsgált kezelés

    The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.

  • Lofexidine (Positive Control)Már használt kezelés, összehasonlításként

    The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.

  • PlaceboPlacebo, összehasonlításként

    The current study is a randomized, double-blind, double-dummy inpatient study comparing BXCL501 (180 and 240 ug BID), lofexidine (as a positive control), and placebo.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal
A regiszteradat frissítve
2026. október 28.